EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieÄquivalenzstudie

Angiotensin Receptor-Neprilysin Inhibition in Patients With STEMI vs NSTEMI

Douglas L Mann, Johny Nicolas, Brian Claggett, Zi Michael Miao, Christopher B Granger, Prafulla Kerkar, Lars Køber, Eldrin F Lewis, John J V McMurray, Aldo P Maggioni, Julio Núñez, Mpiko Ntsekhe und 8 weitere

Journal of the American College of Cardiology · 2024

DOI: 10.1016/j.jacc.2024.01.002 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the American College of Cardiology, 2024. Verfasst von Douglas L Mann und 19 weiteren Autor:innen. Beteiligte Einrichtung: Washington University School of Medicine, St Louis, Missouri, USA. Electronic address: dmann@wustl.edu. Hauptthemen laut MEDLINE: ST Elevation Myocardial Infarction, Non-ST Elevated Myocardial Infarction, Heart Failure, Myocardial Infarction. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Patients who sustain an acute myocardial infarction (AMI), including ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI), remain at high risk for heart failure (HF), coronary events, and death. Angiotensin-converting enzyme inhibitors have been shown to significantly decrease the risk for cardiovascular events in both STEMI and NSTEMI patients. OBJECTIVES: The objectives were to determine whether angiotensin-receptor blockade and neprilysin inhibition with sacubitril/valsartan, compared with ramipril, has impact on reducing cardiovascular events according to the type of AMI. METHODS: The PARADISE-MI (Prospective ARNI versus ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction) trial enrolled patients with AMI complicated by left ventricular dysfunction and/or pulmonary congestion and at least 1 risk-enhancing factor. Patients were randomized to either sacubitril/valsartan or ramipril. The primary endpoint was death from cardiovascular causes or incident HF. In this prespecified analysis, we stratified patients according to AMI type. RESULTS: Of 5,661 enrolled patients, 4,291 (75.8%) had STEMI. These patients were younger and had fewer comorbidities and cardiovascular risk factors than NSTEMI patients. After adjustment for potential confounders, the risk for the primary outcome was marginally higher in NSTEMI vs STEMI patients (adjusted HR: 1.19; 95% CI: 1.00-1.41), with borderline statistical significance (P = 0.05). The primary composite outcome occurred at similar rates in patients randomized to sacubitril/valsartan vs ramipril in STEMI (10% vs 12%; HR: 0.87; 95% CI: 0.73-1.04; P = 0.13) and NSTEMI patients (17% vs 17%; HR: 0.97; 95% CI: 0.75-1.25; P = 0.80; P interaction = 0.53). CONCLUSIONS: Compared with ramipril, sacubitril/valsartan did not significantly decrease the risk for cardiovascular death and HF in patients with AMI complicated by left ventricular dysfunction, irrespective of the type of AMI. (Prospective ARNI vs ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After MI; NCT02924727).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ST Elevation Myocardial InfarctionNon-ST Elevated Myocardial InfarctionHeart FailureMyocardial InfarctionVentricular Dysfunction, LeftHumansNeprilysinRamiprilAngiotensinsReceptors, AngiotensinProspective StudiesTetrazolesTreatment OutcomeValsartanAminobutyratesBiphenyl CompoundsAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor Antagonists

Stichwörter der Autor:innen

acute myocardial infarctionramiprilsacubitril/valsartan

Substanzen

sacubitrilNeprilysinRamiprilAngiotensinsReceptors, AngiotensinTetrazolesValsartanAminobutyratesBiphenyl CompoundsAngiotensin-Converting Enzyme Inhibitors

Autor:innen und Institutionen

  • Washington University School of Medicine, St Louis, Missouri, USA. Electronic address: dmann@wustl.edu.
  • The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA.
  • Duke University Medical Center, Durham, North Carolina, USA.
  • Department of Cardiology, KEM Hospital, Mumbai, Maharashtra, India.
  • Rigshospitalet, Blegdamsvej, Copenhagen, Denmark.

Zitieren

APA

Mann, D. L., Nicolas, J., Claggett, B., Miao, Z. M., Granger, C. B., Kerkar, P., Køber, L., Lewis, E. F., McMurray, J. J. V., Maggioni, A. P., Núñez, J., Ntsekhe, M., Rouleau, J. L., Sim, D., Solomon, S. D., Steg, P. G., van der Meer, P., Braunwald, E., Pfeffer, M. A., & Mehran, R. (2024). Angiotensin Receptor-Neprilysin Inhibition in Patients With STEMI vs NSTEMI. Journal of the American College of Cardiology. https://doi.org/10.1016/j.jacc.2024.01.002

Vancouver

Mann DL, Nicolas J, Claggett B, Miao ZM, Granger CB, Kerkar P, et al. Angiotensin Receptor-Neprilysin Inhibition in Patients With STEMI vs NSTEMI. Journal of the American College of Cardiology. 2024. doi:10.1016/j.jacc.2024.01.002

BibTeX
@article{Mann2024,
  author = {Mann, Douglas L and Nicolas, Johny and Claggett, Brian and Miao, Zi Michael and Granger, Christopher B and Kerkar, Prafulla and Køber, Lars and Lewis, Eldrin F and McMurray, John J V and Maggioni, Aldo P and Núñez, Julio and Ntsekhe, Mpiko and Rouleau, Jean-Lucien and Sim, David and Solomon, Scott D and Steg, Philippe Gabriel and van der Meer, Peter and Braunwald, Eugene and Pfeffer, Marc A and Mehran, Roxana},
  title = {Angiotensin Receptor-Neprilysin Inhibition in Patients With STEMI vs NSTEMI},
  journal = {Journal of the American College of Cardiology},
  year = {2024},
  doi = {10.1016/j.jacc.2024.01.002}
}
Kostenlos starten →